New ABFO Member Company Open Job Posting, Senior Accountant, Poseida Therapeutics

 

Reporting to: Senior Accounting Manager

Position Summary

The Senior Accountant will be responsible for a wide variety of accounting responsibilities. The position requires that the candidate be a hands-on professional with a strong understanding of the application of Generally Accepted Accounting Principles (GAAP) and financial reporting. A SOX-compliant mindset, strong leadership, analytical, and problem-solving skills, and desire and ability to identify, recommend and lead improvements is important.

Responsibilities

These may include but are not limited to:

  • Prepare key monthly reconciliations, with an emphasis on the Company’s clinical trial accruals, fixed asset rollforward, prepaid expenses, etc.
  • Assist with management of quarterly reporting schedule and related deliverables
  • Prepare and review schedules to support the annual audit process
  • Examine contracts to summarize key terms and determine appropriate accounting treatment
  • Adhere to internal control procedures, provide assistance in updating and improving documentation related to internal controls, and assist with annual walkthroughs
  • Ensure compliance with Company accounting and internal control policies as well as GAAP
  • Perform ad hoc reporting and analysis as required
  • Participate in process improvements, financial system enhancements and special projects as needed

Requirements, Knowledge, Skills and Abilities

  • Minimum of Bachelor’s Degree in Accounting or related field with at least 3 years of progressive experience in an accounting role (an equivalent combination of relevant education and applicable job experience may be considered)
  • CPA strongly preferred
  • Public company, biotech/pharmaceutical company, and/or public accounting experience preferred
  • Ability to work independently, coordinating priorities to meet deadlines. Must have ability to set own pace and prioritize multiple projects and deadlines and adapt to changing work priorities
  • Results oriented with strong accounting, financial, analytical, and interpersonal skills
  • Knowledge of US GAAP
  • Strong organization, time management skills, and attention to detail
  • Excellent verbal and written communication skills and possess the ability to communicate effectively with employees of different levels
  • Excellent teamwork and collaboration skills
  • Ability to manage highly confidential material in an appropriate manner
  • Must have an understanding of financial accounting systems and processes
  • Skilled in the use of Microsoft Office Suite with intermediate-to-advanced Excel skills
  • Experience designing, implementing, and documenting policies and procedures in a SOX-compliant environment.
  • Great Plains and Jaggaer experience a plus

Who We Are and What We Do

Poseida Therapeutics is a San Diego-based clinical-stage biopharmaceutical company dedicated to utilizing our proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of cell and gene product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac® DNA Modification System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies.

We are continually innovating and growing as we advance our clinical trial programs. We are passionate about the impact that we will make with our CAR-T therapies in liquid and solid tumor cancers and gene therapies for rare diseases. Our wholly-owned portfolio of product candidates are designed to overcome the primary limitations of current generation cell and gene therapeutics, and includes:

Autologous Programs

  • Our most advanced product candidate, P-BCMA-101, is an autologous CAR-T targeting BCMA that we are currently evaluating in an expanded Phase 1 clinical trial and a Phase 2 clinical trial for the treatment of patients with relapsed/refractory multiple myeloma.
  • We have initiated a Phase 1 clinical trial and are currently dosing patients for our second autologous product candidate targeting PSMA, P-PSMA-101, for the treatment of patients with metastatic-castrate resistant prostate cancer.

Allogeneic Programs

  • Our lead “off-the-shelf” product candidate, P-BCMA-ALLO1 for patients with relapsed/refractory multiple myeloma, is in development and we expect to file an investigational new drug (IND) application and initiation of a Phase 1 clinical trial in late 2020 or early 2021.
  • Additional candidates in preclinical development include P-MUC1C-ALLO1 for multiple solid tumors, with an anticipated IND filing and initiation of a Phase 1 clinical trial in late 2021, as well as P-PSMA-ALLO1 for metastatic castrate-resistant prostate cancer, with an anticipated IND filing and initiation of a Phase 1 clinical trial in late 2022.

DUAL CAR Allogeneic Programs

  • Designed to include two or more fully functional CAR molecules into a T cell, we have preclinical studies ongoing with DUAL CAR (CD19/CD20) in B cell malignancies and DUAL CAR (BCMA/CD19) in multiple myeloma where we anticipate filing INDs and initiating Phase 1 clinical trials in late 2021 and 2022. We also expect to initiate a trial in an undisclosed target in solid tumors in the future.

Gene Therapy Programs for Rare Diseases

  • We are currently developing two liver-directed gene therapies that utilize our proprietary piggyBac® DNA Modification System with AAV/nanoparticle technology – P-OTC-101 for the in vivo treatment of Ornithine Transcarbamylase deficiency, for which we expect to file an IND and initiation of a Phase 1 clinical trial in late 2021 or early 2022. Our second candidate, P-MMUT-101, in Methylmalonic Acidemia, has an anticipated IND filing and initiation of a Phase 1 clinical trial in 2022.

Association of Bioscience Financial Officers

Interested candidates please apply online at https://recruiting.paylocity.com/Recruiting/Jobs/Details/351209

To see this and other open financial positions with our ABFO member companies,
please visit our ABFO website job posting page

THE ASSOCIATION OF BIOSCIENCE FINANCIAL OFFICERS - SOCAL CHAPTER
You are receiving this notice because you have indicated interest in ABFO, are an ABFO Member Representative,
or have come to one of our meetings.
If you have questions or comments or wish to be removed from our distribution list, please contact the ABFO Membership Coordinator, Genie Hawkins at abfogenie@comcast.net